What are Inositol 1 phosphatase inhibitors and how do they work?

ResQ Pharma, Inc., a pharmaceutical company based in Chicago, has announced a significant development regarding its LipidRescue Kit. The company has received a PDUFA (Prescription Drug User Fee Act) date set for June 2, 2025. This date is crucial as it suggests that the new drug application for the LipidRescue Kit is complete and ready for a detailed review by the FDA. If approved, the LipidRescue Kit will be used to treat Local Anesthetic Systemic Toxicity (LAST), a severe and potentially fatal condition that can occur when using local anesthetics such as lidocaine.

LAST, although rare, is a critical event that can happen during the application of local anesthetics in various healthcare environments. Symptoms of LAST typically begin with changes in mental status, such as agitation or confusion, and can quickly progress to severe cardiac issues, including arrhythmias and hypotension. In extreme cases, LAST can lead to seizures, respiratory or cardiac arrest, coma, and even death.

Researching ResQ Pharma Gets PDUFA Date for LipidRescue™ as Potential First FDA-approved LAST Treatment beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore ResQ Pharma Gets PDUFA Date for LipidRescue™ as Potential First FDA-approved LAST Treatment with Hiro LS Researcher →

The LipidRescue Kit, developed by ResQ Pharma, contains a clinically recommended dose of lipid emulsion designed to rapidly counteract the toxic effects of local anesthetic overdose. The kit is innovative, combining LipidRescue with a specially designed administration set that allows for the quick and precise delivery of the lipid emulsion through existing vascular access, bypassing the need for needles. This design is vital for emergency situations where every second counts in saving a patient's life.

Dr. Guy Weinberg, the founder and president of ResQ Pharma, is the inventor of LipidRescue Therapy (LRT). He discovered over 25 years ago that lipid emulsion infusion could reverse severe reactions to local anesthetics. Dr. Weinberg expressed his anticipation for the potential FDA review and approval of the LipidRescue Kit. He acknowledged the support from various physicians, researchers, and advisors who have contributed to the development and potential launch of this life-saving therapy.

The efficacy and safety of LipidRescue are well-documented in numerous preclinical studies and over a hundred peer-reviewed case reports. These studies indicate that when administered according to guidelines, LipidRescue is effective and has minimal adverse reactions. The kit also includes a quick reference guide with clear instructions to ensure that the lipid emulsion is administered correctly and promptly during an emergency.

Mukesh Kumar of FDAMap in Washington, DC, played a consulting role in preparing the New Drug Application for ResQ Pharma and holds the position of Director of Regulatory Affairs at the company. Additionally, Michael Gaba, Vice Chair of Polsinelli's FDA practice group, serves as the outside FDA counsel for ResQ Pharma.

ResQ Pharma is a privately-held biopharmaceutical company dedicated to ensuring the reliable, global use of LipidRescue Therapy (LRT) as a standard treatment for LAST and potentially for various other lipophilic drug overdoses and poisonings. The company was established by Dr. Weinberg, who is also a Professor of Anesthesiology at the University of Illinois College of Medicine. Dr. Weinberg is highly regarded in the anesthesia community and frequently speaks at professional gatherings worldwide.

The introduction of the LipidRescue Kit represents a significant advancement in the treatment of LAST, providing a standardized and effective solution to a life-threatening medical emergency.

Continue your ResQ Pharma Gets PDUFA Date for LipidRescue™ as Potential First FDA-approved LAST Treatment research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What approved and investigational uses have been reported for ResQ Pharma Gets PDUFA Date for LipidRescue™ as Potential First FDA-approved LAST Treatment?
• What is the mechanism of action of ResQ Pharma Gets PDUFA Date for LipidRescue™ as Potential First FDA-approved LAST Treatment, and which targets or pathways are involved?
• Which clinical trials are evaluating ResQ Pharma Gets PDUFA Date for LipidRescue™ as Potential First FDA-approved LAST Treatment, and what outcomes have been reported?
• What patents, publications, and regulatory sources provide the latest evidence on ResQ Pharma Gets PDUFA Date for LipidRescue™ as Potential First FDA-approved LAST Treatment?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.

How to obtain the latest development progress of all targets?

In the Synapse database, you can stay updated on the latest research and development advances of all targets. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!